Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) announced that its wholly owned subsidiary, MindWave Innovations Inc. USA, has entered into a shareholders and joint venture agreement with Singapore-based Skalup Capital Pte Ltd to establish an insurance and technology business in Bermuda under the working brand Monaco Insurance, subject to regulatory approval. The venture will be 75% owned by MindWave and 25% by Skalup, and aims to merge MindWave's blockchain infrastructure and digital-asset-backed capital through staking with Skalup's underwriting expertise and regulatory support.
The joint venture plans to pursue licensing from the Bermuda Monetary Authority (BMA), with initial business lines focused on life annuity products and general insurance. MindWave will lead technology development, including blockchain-based systems designed to digitize insurance contracts, policies and claims processes through its MindChain ecosystem. Skalup will support licensing applications and oversee underwriting operations once regulatory approvals are obtained. The partners also intend to explore reinsurance opportunities through globally rated markets. MindWave will retain ownership of its underlying technology and intellectual property, licensing its use to the venture. Initial activities will focus on incorporation, business planning, licensing applications and platform development, with insurance operations contingent on obtaining the required approvals.
This announcement matters because it represents a significant step for Apimeds into the insurance sector, leveraging blockchain technology to potentially transform traditional insurance processes. By digitizing contracts and claims, the venture could improve efficiency and transparency, while also providing a new revenue stream for Apimeds. The involvement of Skalup brings underwriting and regulatory expertise, which is crucial for navigating Bermuda's insurance market. Bermuda is a well-known hub for insurance and reinsurance, and obtaining a license from the BMA would lend credibility to the venture. For investors, this diversification could enhance Apimeds' growth prospects, although regulatory approval is a key hurdle. The full press release can be viewed at https://ibn.fm/el8k8.
Apimeds Pharmaceuticals US, Inc. is listed on the NYSE American under the ticker APUS, and the latest news and updates relating to the company are available in its newsroom at https://ibn.fm/APUS. The announcement was disseminated through TechMediaWire, a specialized communications platform focused on pioneering companies driving the future of technology. TechMediaWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services. For more information, visit TechMediaWire.


